At week @ , @ % , @ % , @ % , @ % , and @ % of subjects with baseline HbA@c @ % ( @ mmol/mol ) reached HbA@c < @ % with empagliflozin @ mg/linagliptin @ mg , empagliflozin @ mg/linagliptin @ mg , empagliflozin @ mg , empagliflozin @ mg , and linagliptin @ mg , respectively .